

For all appointments

Ph: 4046 7800

Fax: 4051 3028

Email: cairns@qldxray.com.au

Phone lines open from:

7am-9pm Mon to Fri

8am-4pm Sat & Sun

Patient Details

Date:

Name:

DOB:

Address:

Medicare No:

Diagnostic Request. Reason for referral and clinical history

PET/CT Medicare rebateable studies are below. Please tick which items apply. All PET referrals are to be sent to petctcairns@qldxray.com.au

Indication

- Diagnose Restage RT Planning
 Stage Monitor Clinical Trial
 Other _____

Additional Patient Information

- Diabetic
 Melanoma
 Known renal impairment
 Previous contrast reaction
 Public Hospital Outpatient

PET/CT All PETCT scans include relevant diagnostic CT opt out, low dose CTAC only
 Primary/Suspected site _____ Histopathology _____

Lung

- 61523 Solitary Pulmonary Nodule - Diagnosis
 61529 NSCLC - Staging

Brain

- 61538 Brain - Restaging
 61559 Epilepsy - Evaluation
 61560 Alzheimer's - Diagnosis

Lymphoma

- 61620 Staging
 61622 First Line Surveillance - during treatment
 61632 Second Line Surveillance
 61628 Restaging after recurrence

Head & Neck

- 61598 Staging
 61604 Restaging
 61610 Metastatic SCC unknown primary - Staging

Breast

- 61524 PET Breast - Stage III, Staging
 61525 PET Breast - Restaging

Melanoma

- 61553 Restaging

Gynaecology

- 61565 Ovarian - Restaging
 61571 Uterine Cervix - Staging
 61575 Uterine Cervix - Restaging

Sarcoma

- 61640 Bone or Soft Tissue Sarcoma - Staging
 61646 Sarcoma - Restaging

Gastrointestinal

- 61541 Colorectal - Restaging
 61577 Oesophageal/GOJ - Staging
 61647 Gastroenteropancreatic NET - Diagnosis - DOTA Peptide PET

Prostate

- 61563 PSMA Intermediate to high-risk, staging
 61564 PSMA Restaging

Follow-up appointment with Referring Doctor:

Practitioner's Name:

Address:

Signature: _____

Copy to: _____

Thank you for referring your patient to Queensland X-ray.

Queensland X-ray Internal Use Only

Medical Imaging Final Check

- | | Yes | No |
|---------------------------------|--------------------------|--------------------------|
| Pregnant | <input type="checkbox"/> | <input type="checkbox"/> |
| Front Office Check | <input type="checkbox"/> | <input type="checkbox"/> |
| Patient Identification verified | <input type="checkbox"/> | <input type="checkbox"/> |
| Procedure and consent verified | <input type="checkbox"/> | <input type="checkbox"/> |
| Correct side and site verified | <input type="checkbox"/> | <input type="checkbox"/> |

Correct patient data and side markers

Tech initials: _____

Team leader signature: _____


Referring Practitioner's Details

MEDICARE CRITERIA

- 61523 Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed (R).
- 61524 Whole body FDG PET study, performed for the staging of locally advanced (Stage III) breast cancer, for a patient who is considered suitable for active therapy (R) (Anaes.)
- 61525 Whole body FDG PET study, performed for the evaluation of suspected metastatic or suspected locally or regionally recurrent breast carcinoma, for a patient who is considered suitable for active therapy (R) (Anaes.)
- 61529 Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned (R).
- 61538 FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy (R).
- 61541 Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy (R).
- 61553 Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy (R).
- 61559 FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery (R).
- 61560 FDG PET study of the brain, performed for the diagnosis of Alzheimer's disease, if: (a) clinical evaluation of the patient by a specialist, or in consultation with a specialist, is equivocal; and (b) the service includes a quantitative comparison of the results of the study with the results of an FDG PET study of a normal brain from a reference database; and (c) a service to which this item applies has not been performed on the patient in the previous 12 months; and (d) a service to which item 61402 applies has not been performed on the patient in the previous 12 months for the diagnosis or management of Alzheimer's disease. Applicable not more than 3 times per lifetime (R).
- 61563 Whole body PSMA PET study performed for the initial staging of intermediate to high-risk prostate adenocarcinoma, for a previously untreated patient who is considered suitable for locoregional therapy with curative intent.
- 61564 Whole body PSMA PET study performed for the restaging of recurrent prostate adenocarcinoma, for a patient who has undergone prior locoregional therapy and is considered suitable for further locoregional therapy to determine appropriate therapeutic pathways and timing of treatment initiation.
- 61565 Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy (R).
- 61571 Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent (R).
- 61575 Whole body FDG PET study, for the further staging of patients with confirmed local recurrence of carcinoma of the uterine cervix considered suitable for salvage pelvic chemoradiotherapy or pelvic exenteration with curative intent (R).
- 61577 Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy (R).
- 61598 Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer (R).
- 61604 Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy (R).
- 61610 Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes (R).
- 61620 Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma (R).
- 61622 Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma (R).
- 61628 Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma (R).
- 61632 Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma (R).
- 61640 Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable (R).
- 61646 Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent (R).
- 61647 Whole body 68Ga DOTA peptide PET study, if: (a) a gastro entero pancreatic neuroendocrine tumour is suspected on the basis of biochemical evidence with negative or equivocal conventional imaging; or (b) both: (i) a surgically amenable gastro entero pancreatic neuroendocrine tumour has been identified on the basis of conventional techniques; and (ii) the study is for excluding additional disease sites (R).

QUEENSLAND X-RAY LOCATIONS


For all appointments Ph: 4046 7800 Fax: 4051 3028 Email: cairns@qldxray.com.au



CAIRNS PRIVATE HOSPITAL


Level 3, 144 Lake Street
Cairns

New additional free parking is now available on Lake Street, next to Cairns Baptist Church




WESTCOURT AND PET/CT CENTRE

318 Mulgrave Road
Cairns



LAKE STREET

189 Lake Street
Cairns



SMITHFIELD CAIRNS

5 Mt Milman Drive
Smithfield

ONSITE PARKING AT ALL LOCATIONS.

Access your images and results online. Let our friendly reception staff know you'd like to register for the Patient Portal. For more information, please visit qldxray.com.au/patients/results-portal/

DOWNLOAD THE QXR PATIENT APP



Queensland X-ray stores your images for FIVE years. Visit us for all your medical imaging and create a complete and highly secure five-year electronic radiology record which your doctor can access 24/7.

Please ask our team about our concessions for health care and pensioner concession card holders.

Queensland X-Ray Pty Ltd and Queensland X-Ray Hospital Partnership No 23 trading as Queensland X-Ray (a registered business name of Queensland X-Ray Pty Ltd ABN 40 094 502 208). 7025 09/22

Your doctor has recommended you use Queensland X-ray. You may choose another provider but please discuss this with your doctor first.

Printed on Supreme Laser which has the following environmental credentials:

